RxDoctor Payments DataLook up a doctor →

Satish Garg, MD

Endocrinology, Diabetes & Metabolism · Aurora, CONPI 1447264767

Payments from drug & device makers

$8,612,339in general payments, 2019–2025

Across 485 payments — averaging $17,757 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$4.6M
  • Medtronic$3M
  • Eli Lilly$839K
  • Roche Diabetes Care GmbH$79K
  • Novo Nordisk$53K
  • Novo Nordisk AS$23K
  • plus $81K from 20 others
$94,238in research payments, 2019–2025

Across 25 payments — averaging $3769.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$67K
  • Novo Nordisk AS$13K
  • Novo Nordisk$10K
  • Dexcom, Inc.$3K
  • Sanofi-aventis U.S. LLC$2K

What the payments were for

  • Consulting fees$193,99356%
  • Speaking & faculty fees$53,67315%
  • Travel & lodging$90,00126%
  • Food & beverage$8,9183%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,612,339 in reported general payments places this provider in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

See all endocrinology, diabetes & metabolism providers in Colorado

Medicare billing

Part B allowed, 2024
$6,611
Medicare patients
22
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide29$31,064
OzempicSemaglutide15$30,422
Tresiba Flextouch U-200Insulin Degludec14$19,645
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$16,354
Tresiba Flextouch U-100Insulin Degludec17$11,264
Fiasp FlextouchInsulin Aspart (Niacinamide)12$9,336
Humalog Kwikpen U-100Insulin Lispro14$7,673
Insulin Degludec Pen (U-200)Insulin Degludec12$2,234
Levothyroxine Sodium44$551
Losartan Potassium22$373
Simvastatin22$338
Allopurinol33$198
Amlodipine Besylate16$149
Atorvastatin Calcium14$124
Metformin Hcl16$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$53,397$30,42215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

Other endocrinology, diabetes & metabolism in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →